| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | DMOG | GDSC1000 | pan-cancer | AAC | 0.1 | 0.003 |
| mRNA | navitoclax:sorafenib (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.11 | 0.003 |
| mRNA | PD-0325901 | gCSI | pan-cancer | AAC | 0.16 | 0.003 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.14 | 0.004 |
| mRNA | MI-2 | CTRPv2 | pan-cancer | AAC | -0.17 | 0.004 |
| mRNA | BRD-K37390332 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.004 |
| mRNA | Methotrexate | GDSC1000 | pan-cancer | AAC | -0.091 | 0.004 |
| mRNA | BRD-K34222889 | CTRPv2 | pan-cancer | AAC | -0.097 | 0.004 |
| mRNA | dinaciclib | CTRPv2 | pan-cancer | AAC | -0.15 | 0.004 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | -0.097 | 0.004 |